Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-4233
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow ; volume:29 ; number:3 ; day:13 ; month:1 ; year:2022 ; pages:487-497 ; date:5.2022
Breast cancer ; 29, Heft 3 (13.1.2022), 487-497, 5.2022
- Urheber
-
Grüntkemeier, Lisa
Khurana, Aditi
Bischoff, Farideh Zamaniyan
Hoffmann, Oliver
Kimmig, Rainer
Moore, Mathew
Cotter, Philip
Kasimir-Bauer, Sabine
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s12282-022-01330-8
- URN
-
urn:nbn:de:101:1-2022070309015882188253
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:29 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Grüntkemeier, Lisa
- Khurana, Aditi
- Bischoff, Farideh Zamaniyan
- Hoffmann, Oliver
- Kimmig, Rainer
- Moore, Mathew
- Cotter, Philip
- Kasimir-Bauer, Sabine
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer